Abstract: The present application discloses a PEGylated asparaginase and use thereof. In this application, the polyethylene glycol (PEG) is coupled to the N-terminal amino of 1 or 2 subunits of L-asparaginase, and the molecular weight of the PEG is 30-40 KDa. The PEG is preferably branched and has an aldehyde serving as an activating group. The PEGylated asparaginase is useful in the preparation of anti-tumor drugs.
Type:
Grant
Filed:
January 17, 2020
Date of Patent:
August 31, 2021
Assignees:
ZONHON BIOPHARMA INSTITUTE INC., GENSUN INSTITUTE OF BIOMEDICINE CO., LTD.
Inventors:
Bruce Yong Ma, Jun Wang, He Wang, Chunlin Xu, Yifei Chen, Yaofang Wang
Abstract: Described is a bispecific antibody, and a method for producing the bispecific antibody. The bispecific antibody can be used in the preparation of a drug for treating a tumor with high cell expression of CD26. The antibody specifically hinds to human CD26 and human CD3 at the same time.
Type:
Grant
Filed:
October 30, 2015
Date of Patent:
August 25, 2020
Assignees:
ZONHON BIOPHARMA INSTITUTE INC., GENSUN INSTITUTE OF BIOMEDICINE CO., LTD.
Abstract: The present application discloses a PEGylated asparaginase and use thereof. In this application, the polyethylene glycol (PEG) is coupled to the N-terminal amino of 1 or 2 subunits of L-asparaginase, and the molecular weight of the PEG is 30-40 KDa. The PEG is preferably branched and has an aldehyde serving as an activating group. The PEGylated asparaginase is useful in the preparation of anti-tumor drugs.
Type:
Application
Filed:
January 17, 2020
Publication date:
July 16, 2020
Applicants:
ZONHON BIOPHARMA INSTITUTE INC., GENSUN INSTITUTE OF BIOMEDICINE CO., LTD.
Inventors:
Bruce Yong MA, Jun WANG, He WANG, Chunlin XU, Yifei CHEN, Yaofang WANG
Abstract: The present application discloses a PEGylated asparaginase and use thereof. In this application, the polyethylene glycol (PEG) is coupled to the N-terminal amino of 1 or 2 subunits of L-asparaginase, and the molecular weight of the PEG is 30-40 KDa. The PEG is preferably branched and has an aldehyde group serving as an activating group. The PEGylated asparaginase is useful in the preparation of anti-tumor drugs.
Type:
Grant
Filed:
February 3, 2015
Date of Patent:
January 21, 2020
Assignees:
ZONHON BIOPHARMA INSTITUTE INC., GENSUN INSTITUTE OF BIOMEDICINE CO., LTD.
Inventors:
Bruce Yong Ma, Jun Wang, He Wang, Chunlin Xu, Yifei Chen, Yaofang Wang
Abstract: Methods for use of a multi-arm polyethylene glycol (PEG) modifier in modification of asparaginase. The described multi-arm PEG modifier enhances the subunit interaction of a multimeric protein to maintain the multimeric protein in a polymerized form, thereby improving the stability of the multimeric protein, maintaining the bioactivity of the multimeric protein, and reducing the probability of exposure of the antigen binding site after depolymerization of the subunits, so as to reduce the immunogenicity.
Type:
Grant
Filed:
July 28, 2014
Date of Patent:
September 10, 2019
Assignees:
ZONHON BIOPHARMA INSTITUTE INC., GENSUN INSTITUTE OF BIOMEDICINE CO., LTD.
Inventors:
Bruce Yong Ma, Jun Wang, Dinglong Wu, Chunlin Xu, Yaofang Wang
Abstract: The present invention relates to polyethylene glycol (PEG) modified protein drugs, and a PEGylated tissue kallikrein, a preparation method and use thereof are disclosed. The tissue kallikrein has a sequence as shown in SEQ ID No. 1 or SEQ ID No. 2, and the tissue kallikrein may be natural or recombinant. The PEG has a molecular weight of 20 to 40 kDa, and is conjugated to the N-terminal primary amino of the tissue kallikrein. In addition to the advantages of significantly extended half-life, significantly reduced immunogenicity and stable and uniform structure, the biological activity of the PEGylated KLK1 provided in the present invention is improved to a higher extent, which is more significant in the treatment of cerebral apoplexy and diabetic nephropathy in particular.
Type:
Grant
Filed:
January 9, 2014
Date of Patent:
August 21, 2018
Assignees:
ZONHON BIOPHARMA INSTITUTE INC., GENSUN INSTITUTE OF BIOMEDICINE CO., LTD.
Inventors:
Bruce Yong Ma, Jun Wang, Jing Qiu, Dinglong Wu, Chunlin Xu, Chen Chen, Yaofang Wang
Abstract: The present application discloses a PEGylated asparaginase and use thereof. In this application, the polyethylene glycol (PEG) is coupled to the N-terminal amino of 1 or 2 subunits of L-asparaginase, and the molecular weight of the PEG is 30-40 KDa. The PEG is preferably branched and has an aldehyde group serving as an activating group. The PEGylated asparaginase is useful in the preparation of anti-tumor drugs.
Type:
Application
Filed:
February 3, 2015
Publication date:
June 14, 2018
Applicants:
ZONHON BIOPHARMA INSTITUTE INC., GENSUN INSTITUTE OF BIOMEDICINE CO., LTD.
Inventors:
Bruce Yong MA, Jun WANG, He WANG, Chunlin XU, Yifei CHEN, Yaofang WANG
Abstract: Described is a bispecific antibody, and a method for producing the bispecific antibody. The bispecific antibody can be used in the preparation of a drug for treating a tumor with high cell expression of CD26. The antibody specifically hinds to human CD26 and human CD3 at the same time.
Type:
Application
Filed:
October 30, 2015
Publication date:
June 7, 2018
Applicants:
ZONHON BIOPHARMA INSTITUTE INC., GENSUN INSTITUTE OF BIOMEDICINE CO., LTD.
Abstract: The present invention relates to polyethylene glycol (PEG) modified protein drugs, and a PEGylated tissue kallikrein, a preparation method and use thereof are disclosed. The tissue kallikrein has a sequence as shown in SEQ ID No. 1 or SEQ ID No. 2, and the tissue kallikrein may be natural or recombinant. The PEG has a molecular weight of 20 to 40 kDa, and is conjugated to the N-terminal primary amino of the tissue kallikrein. In addition to the advantages of significantly extended half-life, significantly reduced immunogenicity and stable and uniform structure, the biological activity of the PEGylated KLK1 provided in the present invention is improved to a higher extent, which is more significant in the treatment of cerebral apoplexy and diabetic nephropathy in particular.
Type:
Application
Filed:
January 9, 2014
Publication date:
February 23, 2017
Applicants:
ZONHON BIOPHARMA INSTITUTE INC., GENSUN INSTITUTE OF BIOMEDICINE CO.,LTD.
Inventors:
Bruce Yong MA, Jun WANG, Jing QIU, Dinglong WU, Chunlin XU, Chen CHEN, Yaofang WANG
Abstract: Methods for use of a multi-arm polyethylene glycol (PEG) modifier in modification of asparaginase. The described multi-arm PEG modifier enhances the subunit interaction of a multimeric protein to maintain the multimeric protein in a polymerized form, thereby improving the stability of the multimeric protein, maintaining the bioactivity of the multimeric protein, and reducing the probability of exposure of the antigen binding site after depolymerization of the subunits, so as to reduce the immunogenicity.
Type:
Application
Filed:
July 28, 2014
Publication date:
February 16, 2017
Applicants:
ZONHON BIOPHARMA INSTITUTE INC., GENSUN INSTITUTE OF BIOMEDICINE CO.,LTD.
Inventors:
Bruce Yong MA, Jun WANG, Dinglong WU, Chunlin XU, Yaofang WANG